Sigachi Industries Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/pos5lm7bjq7o5b7bth18uqfi.pdf

Key Takeaways


The Hyderabad Incident and Its Aftermath

Amit Raj Sinha: "There is neither a supply side issue nor a market share issue. It is that the plant doesn't turn around so quickly. I wish it was like speeding up on a highway."

MCC Pricing and Product Mix

O.S. Reddy: "If they take this substandard or even unregulated or even those who is not proven in terms of their quality and customer satisfaction if they use, they may incur huge losses or the damage will be on higher side."

Capacity Expansion and New Facilities

Amit Raj Sinha: "We believe that we can scale up the capacity utilization of the proposed new facility much faster, primarily because we have been in the supply chain for the last 30 years selling across 65 countries, selling the same product, established supply chain. So I don't believe that there is a challenge in that."

API Business


Margins and Operating Leverage


Demand Environment

Amit Raj Sinha: "I think that gradually, the smokeless tobacco industry would taper down and would have a steady growth. 30%-40%, is actually unrealistic to maintain."

Funding and Capital Allocation

O.S. Reddy: "Even last time that has some misplanning took place in the last moment because of unexpected holidays. And hope every time it will not happen the same thing."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue guidance₹650–675 crores, "more or less on track"FY27
EBITDA margin18% full-year targetFY27
Dahej-2 MCC expansion12,000 MTPA commissioned, total capacity to 30,000 MTPAQ2 FY28
CCS facility1,800 ton facility to become operationalFY28
Insurance claimFull claim with some discount or ad hoc amount receivedBefore end of September
Insurance receivable₹16.5 crores expected3–4 months
API top lineMore than ₹100–110 croresFY27
UtilizationRun rate beyond 95–96% as company gets closer to year-endFY27 year-end
Q4 exit run rate~95% of 4,500 MT quarterly declared capacity, theoretical capacity ~5,000 MT by thenQ4 FY27
Receivables~90 days by year-end, then 75–80 daysFY27 year-end / undated
Cystic fibrosis product revenue"Maybe next year" or "at the end of the year"FY27 end / FY28

Key Metrics

MetricQ1 FY27
Total operating income₹121.27 crores
EBITDA₹16.5 crores, margin of 13.6%
Net profit₹8.14 crores, PAT margin of 6.76%
MCC segment revenue₹82.74 crores
API segment revenue₹21.68 crores
O&M segment revenue₹13.06 crores
Revenue guidance₹650–675 crores for FY27, no change confirmed
Full-year EBITDA margin guidance18%, management confirmed on track
MCC average realization₹241.36 per kg, up from ₹216 per kg in Q4
Capacity utilization76.8% overall; Dahej 76.5%; Jhagadia 77.16%
Cellulose-based excipient capacity18,000 metric tons per annum, export share over 53.5% of production
Dahej-2 MCC expansion12,000 metric tons per annum, commissioning targeted Q2 FY28, taking total capacity to 30,000 metric tons per annum
Croscarmellose Sodium facility1,800 tons at Dahej SEZ, operational in FY28
API full-year expectationMore than ₹100 crores to ₹110 crores, or even more
FY27 capexMore than ₹100 crores
FY28 capex₹150 crores to ₹200 crores
Receivables days93–94 days currently, target of 90 days by year-end, further target of 75–80 days
Insurance claim receivable₹16.5 crores eligible from business continuity policy of ₹25 crores, expected in 3–4 months
Compensation paid per deceased beneficiary₹42 lakhs each